Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

Cash to Debt 0.08
FMSPR's Cash to Debt is ranked higher than
56% of the 242 Companies
in the Global Medical Care industry.

( Industry Median: 0.22 vs. FMSPR: 0.08 )
FMSPR' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 0.08

Equity to Asset 0.40
FMSPR's Equity to Asset is ranked higher than
66% of the 234 Companies
in the Global Medical Care industry.

( Industry Median: 0.45 vs. FMSPR: 0.40 )
FMSPR' s 10-Year Equity to Asset Range
Min: 0.34   Max: 0.5
Current: 0.4

Interest Coverage 5.04
FMSPR's Interest Coverage is ranked higher than
68% of the 155 Companies
in the Global Medical Care industry.

( Industry Median: 5.49 vs. FMSPR: 5.04 )
FMSPR' s 10-Year Interest Coverage Range
Min: 1.6   Max: 9999.99
Current: 5.04

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

Operating margin (%) 15.44
FMSPR's Operating margin (%) is ranked higher than
89% of the 236 Companies
in the Global Medical Care industry.

( Industry Median: 9.44 vs. FMSPR: 15.44 )
FMSPR' s 10-Year Operating margin (%) Range
Min: 7.8   Max: 16.51
Current: 15.44

Net-margin (%) 7.60
FMSPR's Net-margin (%) is ranked higher than
83% of the 236 Companies
in the Global Medical Care industry.

( Industry Median: 4.97 vs. FMSPR: 7.60 )
FMSPR' s 10-Year Net-margin (%) Range
Min: -6.47   Max: 8.6
Current: 7.6

ROE (%) 12.02
FMSPR's ROE (%) is ranked higher than
82% of the 229 Companies
in the Global Medical Care industry.

( Industry Median: 8.44 vs. FMSPR: 12.02 )
FMSPR' s 10-Year ROE (%) Range
Min: -12.41   Max: 13.71
Current: 12.02

ROA (%) 4.80
FMSPR's ROA (%) is ranked higher than
78% of the 237 Companies
in the Global Medical Care industry.

( Industry Median: 3.63 vs. FMSPR: 4.80 )
FMSPR' s 10-Year ROA (%) Range
Min: -4.32   Max: 5.72
Current: 4.8

ROC (Joel Greenblatt) (%) 38.82
FMSPR's ROC (Joel Greenblatt) (%) is ranked higher than
87% of the 235 Companies
in the Global Medical Care industry.

( Industry Median: 16.84 vs. FMSPR: 38.82 )
FMSPR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 26.11   Max: 58.83
Current: 38.82

» FMSPR's 10-Y Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with FMSPR

No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Fresenius Medical Care AG & Co. KGaA



Current Ratio 1.88
FMSPR's Current Ratio is ranked higher than
85% of the 238 Companies
in the Global Medical Care industry.

( Industry Median: 1.39 vs. FMSPR: 1.88 )
FMSPR' s 10-Year Current Ratio Range
Min: 0.8   Max: 1.93
Current: 1.88

Quick Ratio 1.53
FMSPR's Quick Ratio is ranked higher than
79% of the 238 Companies
in the Global Medical Care industry.

( Industry Median: 1.24 vs. FMSPR: 1.53 )
FMSPR' s 10-Year Quick Ratio Range
Min: 0.7   Max: 1.61
Current: 1.53


Dividend & Buy Back

Dividend Yield 1.06
FMSPR's Dividend Yield is ranked higher than
52% of the 144 Companies
in the Global Medical Care industry.

( Industry Median: 1.53 vs. FMSPR: 1.06 )
FMSPR' s 10-Year Dividend Yield Range
Min: 0   Max: 0
Current: 1.06

Yield on cost (5-Year) 1.06
FMSPR's Yield on cost (5-Year) is ranked higher than
56% of the 145 Companies
in the Global Medical Care industry.

( Industry Median: 1.97 vs. FMSPR: 1.06 )
FMSPR' s 10-Year Yield on cost (5-Year) Range
Min: 0   Max: 0
Current: 1.06

Valuation & Return


Business Description

Industry: Health Care Providers » Medical Care
Compare: » details
Traded in other countries:0H9X.country, FMCMF.USA, FMEA.Germany, FME.Germany, FMEN.Germany, FME3.Germany, 0EH5.country, FMCQF.USA, 0QJE.country
Fresenius Medical Care AG & Co. KGaA was originally incorporated on August 5, 1996. It is a kidney dialysis company, operating in both the field of dialysis products and the field of dialysis services. The Company's dialysis business is vertically integrated, providing dialysis treatment at its own dialysis clinics and supplying these clinics with a range of products. In addition, it sells dialysis products to other dialysis service providers. It also develops and manufactures equipment, systems and disposable products, which it sells to customers in over 120 countries. It offers life-maintaining and life-saving dialysis services and products in a market which is characterized by a favorable demographic development. It provides expanded and enhanced patient services, including renal pharmaceutical products and laboratory services, to both its own clinics and those of third parties. The Company has developed disease state management methodologies, which involve the coordination of holistic patient care for ESRD patients and which are attractive to managed care payors. It provides ESRD and chronic kidney disease management programs to about 4,000 patients. The Company's clinics also provide services for home dialysis patients, the majority of whom receive peritoneal dialysis treatment. It also provides dialysis services under contract to hospitals in the U.S. on an 'as needed' basis for hospitalized ESRD patients and for patients suffering from acute kidney failure. The Company provides laboratory testing and marketing services in the U.S. through Spectra Laboratories (Spectra). Spectra provides blood, urine and other bodily fluid testing services to determine the appropriate individual dialysis therapy for a patient and to assist physicians in determining whether a dialysis patient's therapy regimen, diet and medicines remain optimal. The Company's main trademarks are the name 'Fresenius' and the 'F' logo'. The Company's competitors in the sale of hemodialysis and peritoneal dialysis products include, Baxter International Inc., Asahi Kasei Kuraray Medical Co. Ltd., Bellco S.r.l., B. Braun Melsungen AG, Nipro Corporation Ltd., Nikkiso Co., Ltd., Terumo Corporation, Kawasumi Laboratories Inc., Fuso Pharmaceuticals Industries Ltd., and Toray Industries, Inc. The Company's operations are subject to extensive governmental regulation by virtually every country in which it operates including the U.S., at the federal, state and local levels.

Personalized Checklist

Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
Email Hide